BAXFENDY (Baxdrostat) Patent Expiration, LOE Window & CMS Spending

BAXFENDY (Baxdrostat) by AstraZeneca: FDA Orange Book core substance LOE 2033-02-04, 0 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAstraZeneca
FDA Application & PathwayN219878 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2033-02-04
Last Listed Patent or Exclusivity Date2033-02-04
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AstraZeneca across sibling Meru public-data platforms.